TBPH Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for TBPH from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Theravance Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.59 |
| 52 Week High | US$11.71 |
| 52 Week Low | US$7.44 |
| Beta | 0.22 |
| 1 Month Change | 1.27% |
| 3 Month Change | 20.78% |
| 1 Year Change | -13.13% |
| 3 Year Change | -11.04% |
| 5 Year Change | -62.80% |
| Change since IPO | -58.23% |
Recent News & Updates
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For
Nov 12
We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow
Jul 16Recent updates
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For
Nov 12We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow
Jul 16Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now
May 02Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S
Feb 05Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11Theravance to purchase $95M of ordinary shares
Sep 28Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma announces $250M capital return program
Sep 19Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M
Aug 04Theravance: All-Round Failure
Mar 10Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study
Jun 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Shareholder Returns
| TBPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.9% | -1.5% | -2.4% |
| 1Y | -13.1% | 7.9% | 23.4% |
Return vs Industry: TBPH underperformed the US Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: TBPH underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| TBPH volatility | |
|---|---|
| TBPH Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TBPH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TBPH's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 99 | Rick Winningham | www.theravance.com |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
Theravance Biopharma, Inc. Fundamentals Summary
| TBPH fundamental statistics | |
|---|---|
| Market cap | US$471.58m |
| Earnings (TTM) | -US$49.40m |
| Revenue (TTM) | US$63.19m |
7.5x
P/S Ratio-9.5x
P/E RatioIs TBPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBPH income statement (TTM) | |
|---|---|
| Revenue | US$63.19m |
| Cost of Revenue | US$36.50m |
| Gross Profit | US$26.69m |
| Other Expenses | US$76.09m |
| Earnings | -US$49.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 42.23% |
| Net Profit Margin | -78.18% |
| Debt/Equity Ratio | 0% |
How did TBPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:38 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Theravance Biopharma, Inc. is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Tazeen Ahmad | BofA Global Research |
| Julian Harrison | BTIG |